Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Imunon Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IMNN
Nasdaq
8731
https://imunon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Imunon Inc
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
- May 13th, 2024 1:00 pm
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
- May 13th, 2024 12:00 pm
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
- May 8th, 2024 12:00 pm
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
- May 6th, 2024 3:00 pm
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
- Apr 18th, 2024 12:30 pm
IMNN: IND Application Submitted for Phase 1/2 Trial of Seasonal COVID-19 Vaccine…
- Apr 12th, 2024 10:41 am
IMUNON Reports Compliance with Nasdaq Listing Requirements
- Apr 11th, 2024 12:00 pm
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 11:08 pm
IMUNON Reports 2023 Financial Results and Provides Business Update
- Mar 28th, 2024 12:00 pm
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
- Mar 25th, 2024 12:30 pm
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
- Mar 21st, 2024 9:00 pm
IMUNON Files IND Application to Begin Human Testing of IMNN-101
- Mar 13th, 2024 12:00 pm
IMUNON Announces Leadership Change
- Mar 12th, 2024 9:00 pm
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
- Feb 29th, 2024 1:30 pm
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
- Feb 27th, 2024 1:30 pm
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
- Feb 22nd, 2024 1:00 pm
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dec 11th, 2023 1:30 pm
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript
- Nov 20th, 2023 11:45 pm
IMNN: Promising Interim PFS and OS Data for IMNN-001 in OVATION 2 Trial…
- Nov 17th, 2023 2:11 pm
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
- Nov 14th, 2023 2:00 pm
Scroll